SOURCE: OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals, Inc.

April 12, 2016 11:12 ET

OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax® in Hong Kong

BATON ROUGE, LA--(Marketwired - April 12, 2016) -  OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance for a patent on ProscaVax®, OncBioMune's cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from Hong Kong's patent office.

The patent, titled "Composition and Method for Treating Cancer," application number 14101607.7, expands the scope of protection of OncBioMune's intellectual property, which now includes 15 patents and patents pending covering approximately 50 countries worldwide for the Company's vaccine and paclitaxel gallium transferrin (PGT) technologies.

ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigen PSA with biological adjuvants to selectively target tumor cells without damaging healthy cells. OncBioMune is in the process of enrolling and treating the final four patients in a Department of Defense-funded Phase 1a trial of ProscaVax in late-stage cancer patients hosted at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California. As recently disclosed, OncBioMune is using the data from the Phase 1a trial, that shows very minimal toxicity of ProscaVax, to forego the Phase 1b portion of the ongoing trial and to initiate two Phase 2 clinical trials of ProscaVax in 2016. One study is planned to be hosted at a major university in the Northeast United States and will enroll early-stage cancer patients in the "active surveillance" population. The second, to be conducted in Mexico through a joint venture with Vitel Laboratorios S.A. de C.V., will evaluate ProscaVax for the treatment of PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients.

Prostate cancer is the third most common cancer in men in Hong Kong, accounting for approximately 11.1 percent of all newly diagnosed cancer cases annually.

"As we've shown with our recent partnership to develop and commercialize ProscaVax throughout Mexico and Latin America, we intend to remain active in exploring opportunities worldwide for our novel vaccine," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Prostate cancer is a global problem with limited treatments that are safe and effective without morbidities. Given that ProscaVax has the potential to treat the disease at any stage, patents to protect our intellectual property are very important for our ongoing developmental efforts."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax® is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information

  • INVESTOR AND MEDIA CONTACT:
    OncBioMune Pharmaceuticals, Inc.
    Andrew Kucharchuk
    President and Chief Financial Officer
    akucharchuk@oncbiomune.com